Pfizer Net Profit Margin 2012-2026 | PFE
Current and historical net profit margin for Pfizer (PFE) from 2012 to 2026. Net profit margin can be defined as net Income as a portion of total sales revenue. Pfizer net profit margin for the three months ending March 31, 2026 was .
| Pfizer Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2026-03-31 | $63.32B | $7.49B | 11.83% |
| 2025-12-31 | $62.58B | $7.77B | 12.42% |
| 2025-09-30 | $62.79B | $9.83B | 15.65% |
| 2025-06-30 | $63.83B | $10.75B | 16.84% |
| 2025-03-31 | $62.46B | $7.88B | 12.62% |
| 2024-12-31 | $63.63B | $8.03B | 12.62% |
| 2024-09-30 | $60.43B | $4.25B | 7.04% |
| 2024-06-30 | $56.22B | $-2.60B | -4.62% |
| 2024-03-31 | $55.95B | $-0.31B | -0.55% |
| 2023-12-31 | $59.55B | $2.12B | 3.56% |
| 2023-09-30 | $70.12B | $10.48B | 14.95% |
| 2023-06-30 | $79.27B | $21.47B | 27.09% |
| 2023-03-31 | $94.00B | $29.05B | 30.91% |
| 2022-12-31 | $101.18B | $31.37B | 31.01% |
| 2022-09-30 | $99.88B | $29.77B | 29.81% |
| 2022-06-30 | $101.28B | $29.31B | 28.94% |
| 2022-03-31 | $92.43B | $24.97B | 27.01% |
| 2021-12-31 | $81.29B | $21.98B | 27.04% |
| 2021-09-30 | $68.88B | $19.43B | 28.21% |
| 2021-06-30 | $55.12B | $12.76B | 23.14% |
| 2021-03-31 | $46.08B | $10.68B | 23.18% |
| 2020-12-31 | $41.65B | $9.16B | 21.99% |
| 2020-09-30 | $32.07B | $7.73B | 24.10% |
| 2020-06-30 | $34.47B | $13.94B | 40.44% |
| 2020-03-31 | $37.87B | $15.50B | 40.92% |
| 2019-12-31 | $40.91B | $16.03B | 39.18% |
| 2019-09-30 | $40.22B | $16.22B | 40.32% |
| 2019-06-30 | $40.84B | $12.65B | 30.98% |
| 2019-03-31 | $41.04B | $11.48B | 27.97% |
| 2018-12-31 | $40.83B | $11.15B | 27.32% |
| 2018-09-30 | $53.37B | $23.82B | 44.63% |
| 2018-06-30 | $53.24B | $22.55B | 42.35% |
| 2018-03-31 | $52.67B | $21.75B | 41.29% |
| 2017-12-31 | $52.55B | $21.31B | 40.55% |
| 2017-09-30 | $52.47B | $9.81B | 18.69% |
| 2017-06-30 | $52.35B | $8.32B | 15.90% |
| 2017-03-31 | $52.60B | $7.30B | 13.88% |
| 2016-12-31 | $52.82B | $7.22B | 13.66% |
| 2016-09-30 | $53.24B | $6.27B | 11.77% |
| 2016-06-30 | $52.29B | $7.04B | 13.47% |
| 2016-03-31 | $50.99B | $7.62B | 14.95% |
| 2015-12-31 | $48.85B | $6.96B | 14.25% |
| 2015-09-30 | $47.92B | $8.36B | 17.45% |
| 2015-06-30 | $48.20B | $8.90B | 18.46% |
| 2015-03-31 | $49.12B | $9.18B | 18.69% |
| 2014-12-31 | $49.61B | $9.14B | 18.42% |
| 2014-09-30 | $50.05B | $10.48B | 20.93% |
| 2014-06-30 | $50.33B | $10.40B | 20.66% |
| 2014-03-31 | $50.53B | $21.58B | 42.71% |
| 2013-12-31 | $51.58B | $22.00B | 42.65% |
| 2013-09-30 | $50.88B | $25.75B | 50.61% |
| 2013-06-30 | $51.19B | $26.37B | 51.51% |
| 2013-03-31 | $52.18B | $15.53B | 29.75% |
| 2012-12-31 | $54.66B | $14.57B | 26.66% |
| 2012-09-30 | $53.25B | $9.69B | 18.21% |
| 2012-06-30 | $56.90B | $10.22B | 17.97% |
| 2012-03-31 | $59.42B | $9.58B | 16.12% |
| 2011-12-31 | $61.04B | $10.01B | 16.40% |
| 2011-09-30 | $65.06B | $11.46B | 17.62% |
| 2011-06-30 | $64.44B | $8.59B | 13.33% |
| 2011-03-31 | $65.09B | $8.45B | 12.99% |
| 2010-12-31 | $65.17B | $8.26B | 12.67% |
| 2010-09-30 | $65.50B | $6.13B | 9.36% |
| 2010-06-30 | $61.13B | $8.15B | 13.33% |
| 2010-03-31 | $54.98B | $7.93B | 14.43% |
| 2009-12-31 | $49.27B | $8.64B | 17.53% |
| 2009-09-30 | $45.82B | $8.13B | 17.75% |
| 2009-06-30 | $46.17B | $7.53B | 16.32% |
| 2009-03-31 | $47.32B | $8.05B | 17.01% |
| 2008-12-31 | $48.30B | $8.10B | 16.78% |
| 2008-09-30 | $48.82B | $10.56B | 21.63% |
| 2008-06-30 | $48.84B | $9.05B | 18.52% |
| 2008-03-31 | $47.79B | $7.54B | 15.77% |
| 2007-12-31 | $48.42B | $8.14B | 16.82% |
| 2007-09-30 | $48.15B | $14.87B | 30.88% |
| 2007-06-30 | $48.44B | $17.47B | 36.06% |
| 2007-03-31 | $49.10B | $18.62B | 37.92% |
| 2006-12-31 | $48.37B | $19.34B | 39.98% |
| 2006-09-30 | $47.37B | $12.62B | 26.64% |
| 2006-06-30 | $46.35B | $10.85B | 23.40% |
| 2006-03-31 | $46.06B | $11.90B | 25.82% |
| 2005-12-31 | $47.41B | $8.09B | 17.06% |
| 2005-09-30 | $47.20B | $8.18B | 17.33% |
| 2005-06-30 | $48.77B | $9.93B | 20.36% |
| 2005-03-31 | $49.59B | $9.33B | 18.82% |
| 2004-12-31 | $48.99B | $11.36B | 23.19% |
| 2004-09-30 | $51.57B | $9.14B | 17.71% |
| 2004-06-30 | $51.09B | $8.03B | 15.72% |
| 2004-03-31 | $48.72B | $1.58B | 3.24% |
| 2003-12-31 | $44.74B | $3.91B | 8.74% |
| 2003-09-30 | $40.01B | $6.17B | 15.41% |
| 2003-06-30 | $35.66B | $6.28B | 17.61% |
| 2003-03-31 | $33.05B | $11.83B | 35.78% |
| 2002-12-31 | $32.29B | $9.13B | 28.26% |
| 2002-09-30 | $29.03B | $8.23B | 28.34% |
| 2002-06-30 | $28.86B | $7.95B | 27.54% |
| 2002-03-31 | $29.19B | $7.82B | 26.80% |
| 2001-12-31 | $29.02B | $7.79B | 26.83% |
| 2001-09-30 | $31.14B | $7.25B | 23.29% |
| 2001-06-30 | $30.47B | $6.54B | 21.46% |
| 2001-03-31 | $29.84B | $5.86B | 19.64% |
| 2000-12-31 | $29.41B | $3.73B | 12.67% |
| 2000-09-30 | $25.81B | $3.26B | 12.63% |
| 2000-06-30 | $21.99B | $3.30B | 15.00% |
| 2000-03-31 | $18.78B | $2.86B | 15.21% |
| 1999-12-31 | $15.54B | $3.88B | 24.93% |
| 1999-09-30 | $14.90B | $3.63B | 24.37% |
| 1999-06-30 | $14.90B | $3.63B | 24.37% |
| 1999-03-31 | $14.24B | $3.55B | 24.94% |
| 1998-12-31 | $13.35B | $3.43B | 25.69% |
| 1998-09-30 | $12.39B | $3.28B | 26.43% |
| 1998-06-30 | $11.71B | $2.47B | 21.13% |
| 1998-03-31 | $11.09B | $2.30B | 20.77% |
| 1997-12-31 | $10.74B | $2.21B | 20.61% |
| 1997-09-30 | $10.99B | $2.16B | 19.65% |
| 1997-06-30 | $11.14B | $2.08B | 18.64% |
| 1997-03-31 | $11.31B | $2.01B | 17.81% |
| 1996-12-31 | $11.31B | $1.93B | 17.06% |
| 1996-09-30 | $10.89B | $1.84B | 16.86% |
| 1996-06-30 | $10.63B | $1.75B | 16.44% |
| 1996-03-31 | $10.37B | $1.67B | 16.10% |
| 1995-12-31 | $10.02B | $1.57B | 15.69% |
| 1995-09-30 | $9.58B | $1.50B | 15.61% |
| 1995-06-30 | $9.11B | $1.41B | 15.44% |
| 1995-03-31 | $8.64B | $1.35B | 15.61% |
| 1994-12-31 | $8.28B | $1.30B | 15.69% |
| 1994-09-30 | $7.97B | $1.25B | 15.73% |
| 1994-06-30 | $7.77B | $0.70B | 9.05% |
| 1994-03-31 | $7.59B | $0.70B | 9.22% |
| 1993-12-31 | $7.48B | $0.66B | 8.80% |
| 1993-09-30 | $7.44B | $0.65B | 8.71% |
| 1993-06-30 | $7.39B | $1.16B | 15.69% |
| 1993-03-31 | $7.34B | $1.13B | 15.35% |
| 1992-12-31 | $7.23B | $1.08B | 14.88% |
| 1992-09-30 | $7.13B | $0.80B | 11.19% |
| 1992-06-30 | $7.08B | $0.78B | 10.95% |
| 1992-03-31 | $7.02B | $0.73B | 10.46% |
| 1991-12-31 | $6.95B | $0.72B | 10.39% |
| 1991-09-30 | $6.89B | $0.88B | 12.72% |
| 1991-06-30 | $6.76B | $0.84B | 12.49% |
| 1991-03-31 | $6.62B | $0.82B | 12.33% |
| 1990-12-31 | $6.41B | $0.80B | 12.50% |
| 1990-09-30 | $6.12B | $0.73B | 11.99% |
| 1990-06-30 | $5.91B | $0.71B | 11.98% |
| 1990-03-31 | $5.72B | $0.69B | 12.12% |
| 1989-12-31 | $5.67B | $0.68B | 12.02% |
| 1989-09-30 | $5.55B | $0.74B | 13.29% |
| 1989-06-30 | $5.49B | $0.74B | 13.41% |
| 1989-03-31 | $5.52B | $0.81B | 14.72% |
| 1988-12-31 | $5.39B | $0.79B | 14.71% |
| 1988-09-30 | $5.29B | $0.79B | 14.87% |
| 1988-06-30 | $5.21B | $0.76B | 14.52% |
| 1988-03-31 | $5.10B | $0.72B | 14.10% |
| 1987-12-31 | $4.92B | $0.69B | 14.04% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |